We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

433 hedge funds and large institutions have $3.52B invested in CRISPR Therapeutics in 2025 Q2 according to their latest regulatory filings, with 101 funds opening new positions, 127 increasing their positions, 101 reducing their positions, and 60 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more first-time investments, than exits

New positions opened: 101 | Existing positions closed: 60

60% more capital invested

Capital invested by funds: $2.2B → $3.52B (+$1.32B)

31% more call options, than puts

Call options by funds: $244M | Put options by funds: $186M

26% more repeat investments, than reductions

Existing positions increased: 127 | Existing positions reduced: 101

9% more funds holding

Funds holding: 396 → 433 (+37)

8.4% more ownership

Funds ownership: 75.39% → 83.79% (+8.4%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

Holders
433
Holders Change
+37
Holders Change %
+9.34%
% of All Funds
5.7%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
101
Increased
127
Reduced
101
Closed
60
Calls
$244M
Puts
$186M
Net Calls
+$58.2M
Net Calls Change
+$37.5M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$134M
2
OAG
Orbis Allan Gray
Bermuda
+$46.5M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$39.7M
4
State Street
State Street
Massachusetts
+$33.3M
5
UBS Group
UBS Group
Switzerland
+$29.9M

Top Sellers

Rank Fund Capital Flow
1
UBS AM
UBS AM
Illinois
-$38.2M
2
Morgan Stanley
Morgan Stanley
New York
-$30.5M
3
BBA
Baker Bros. Advisors
New York
-$22.3M
4
Millennium Management
Millennium Management
New York
-$19.9M
5
Capital International Investors
Capital International Investors
California
-$18.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Rockefeller Capital Management
51
Rockefeller Capital Management
New York
$5.61M +$962K +24,853 +27%
Rafferty Asset Management
52
Rafferty Asset Management
New York
$5.56M -$1.23M -31,684 -22%
PAG
53
Private Advisor Group
New Jersey
$5.45M +$137K +3,531 +3%
RMCM
54
Reynders McVeigh Capital Management
Massachusetts
$5.42M +$374K +9,658 +9%
Mirae Asset Global ETFs Holdings
55
Mirae Asset Global ETFs Holdings
Hong Kong
$5.12M +$1.16M +30,065 +40%
California Public Employees Retirement System
56
California Public Employees Retirement System
California
$5.04M +$310K +8,011 +8%
IHAM
57
Integral Health Asset Management
New York
$4.86M -$1.93M -50,000 -33%
Raymond James Financial
58
Raymond James Financial
Florida
$4.75M +$422K +10,907 +13%
CRB
59
Chad R. Baker
$4.53M – – –
EWA
60
EverSource Wealth Advisors
Alabama
$4.52M +$312K +8,063 +9%
CIS
61
Capital International Sarl
California
$4.45M -$442K -11,425 -11%
Wealth Enhancement Advisory Services
62
Wealth Enhancement Advisory Services
Minnesota
$4.31M -$445K -11,493 -12%
AllianceBernstein
63
AllianceBernstein
Tennessee
$4.21M +$3.35M +86,620 New
HCS
64
Himension Capital (Singapore)
Singapore
$4.04M -$405K -10,454 -11%
VanEck Associates
65
VanEck Associates
New York
$4.04M – – –
SC
66
Slow Capital
California
$3.67M +$393K +10,152 +16%
California State Teachers Retirement System (CalSTRS)
67
California State Teachers Retirement System (CalSTRS)
California
$3.64M +$200K +5,165 +7%
Millennium Management
68
Millennium Management
New York
$3.41M -$19.9M -513,640 -88%
CAM
69
Congress Asset Management
Massachusetts
$3.33M +$3.95K +102 +0.1%
Envestnet Asset Management
70
Envestnet Asset Management
Illinois
$3.3M -$4.49K -116 -0.2%
Invesco
71
Invesco
Georgia
$3.24M +$1.5M +38,691 +138%
T. Rowe Price Associates
72
T. Rowe Price Associates
Maryland
$3.23M +$1.51M +39,004 +143%
DSCM
73
Del-Sette Capital Management
New York
$3.11M +$2.47M +63,843 New
Commonwealth Equity Services
74
Commonwealth Equity Services
Massachusetts
$3.04M -$476K -12,308 -16%
CI
75
Capital International
California
$2.99M -$407K -10,511 -15%
1 2
3
4 5

CRSP Hedge Fund Activity: Q2 2025 in Review

433 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2025, worth a combined $3.52B — up 60% from $2.2B a quarter earlier.

Buyers outnumbered sellers: 101 funds opened new CRSP positions and 60 closed out — a net gain of 41 holders — while 127 added to existing stakes and 101 trimmed.

The largest buyer was BlackRock, adding an estimated $134M. The largest seller was UBS AM, cutting an estimated $38.2M.

  • 433 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2025, up from 396 in Q1 2025.
  • Funds reported $3.52B of CRISPR Therapeutics stock for Q2 2025, up 60% quarter-over-quarter.
  • 101 funds opened new CRISPR Therapeutics positions in Q2 2025 and 60 closed out, a net change of +41 holders.
  • The largest CRISPR Therapeutics buyer in Q2 2025 was BlackRock, an estimated $134M added.
  • The largest CRISPR Therapeutics seller in Q2 2025 was UBS AM, an estimated $38.2M sold.

Based on aggregated 13F filings for Q2 2025.